Tuberculosis Diagnostics: Improving TB Management and Multidrug-Resistance with Abbott's RealTime MTB* & RealTime MTB RIF/INH Resistance*

06:30 EDT 27 Jul 2015 | BioPortfolio


Tuberculosis (TB) – an infectious disease caused by a bacterium called Mycobacterium TB (MTB) – is a major global health care problem, and the number of multidrug-resistant TB (MDR-TB) cases is increasing.1
MDR-TB is a form of TB caused by bacteria that does not respond to isoniazid (INH) and rifampicin (RIF), the two most powerful, first-line (or standard) anti-TB drugs.1 Isoniazid resistance is now the most common type of TB infection resistance worldwide.2
Nearly 500,000 people have developed MDR-TB and only 45 % of the MDR-TB patients who could have been detected were diagnosed and notified in 2013.1
On average, approximately one in ten TB patients determined to be sensitive to rifampicin will have isoniazid resistance that cannot be detected by some technology currently recommended by the World Health Organization.1 Detection of rifampicin resistance alone raises a concern that TB strains with resistance to other first-line anti-TB drugs will be missed, and inappropriate treatment might be given.3

So how does Abbott contribute to the fight against MDR-TB?

Firstly, the Abbott RealTime MTB assay (CE-marked) provides high sensitivity for the qualitative detection of MTB and is intended as an aid in diagnosing TB infections, even in samples with low bacterial load (smear negative, culture positive specimen), so patients can begin treatment immediately.
Secondly, the recently CE-marked Abbott RealTime MTB RIF/INH Resistance assay offers qualitative detection of rifampicin and isoniazid resistance in positive MTB samples, allowing for fast availability of resistance results as well as improved workflow efficiency.
Both assays are part of the broad infectious disease test menu available on Abbott’s automated m2000 RealTime System that includes HIV-1 viral load, HIV-1 qualitative for Early Infant Diagnosis, HCV viral load, HBV viral load, HPV, CT/NG, among others.


1. WHO Global TB Report 2014
2. Wang T-Y et al, PLoS ONE 9(1): e86316. doi:10.1371/journal.pone.0086316
3. Fasih N et al, 2012 PLoS ONE 7(11): e50551. doi:10.1371/journal.pone.0050551


More From BioPortfolio on "Tuberculosis Diagnostics: Improving TB Management and Multidrug-Resistance with Abbott's RealTime MTB* & RealTime MTB RIF/INH Resistance*"

Quick Search


Relevant Topics

Tuberculosis TB
Tuberculosis (TB) is an infectious disease caused by bacteria belonging to the Mycobacterium tuberculosis complex. Over nine million new cases of TB, and nearly two million deaths from TB, are estimated to occur around the world every year, and new inf...

Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

The 11th largest pharmaceutical company in the world, <!--LGfEGNT2Lhm-->Abbott Laboratories generated sales of $16 billion in 2009 and has 90,000 employees. Within the <!--LGfEGNT2Lhm-->medical device arm of the company, products of note ar...